

Please type a plus sign (+) inside this box ☐

PTO/SB/08A (10-96)

Approved for use through 10/31/99. OMB 0651-0031

Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

5, no persons are required to respond to a collection of information unless it contains a valid OMB control number.


INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Complete if Known	
				Application Number	09/414,091
				Filing Date	October 7, 1999
				First Named Inventor	Stavros C. Manolagas, et al.
				Group Art Unit	1614
Sheet	1	of	5	Examiner Name	
				Attorney Docket No.	06572.105002

U.S. PATENT DOCUMENTS						
Examiner Initials*	Cite No.	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code (if known)			
R	AA	5,885,973		Papapoulos et al.	03-23-1999	
	AB	5,859,001		Simpkins et al.	01-12-1999	
	AC	5,843,934		Simpkins, J.W.	12-01-1998	
	AD	5,824,672		Simpkins et al.	10-20-1998	
	AE	5,753,649		Tahara et al.	05-19-1998	
	AF	5,750,746		DeLuca et al.	05-12-1998	
	AG	5,674,844		Kuberasampath et al.	10-07-1997	
	AH	5,663,195		Scolnick	09-02-1997	
	AI	5,618,549		Patat et al.	04-08-1997	
	AJ	5,604,259		Jee	02-18-1997	
	AK	5,593,988		Tahara et al.	01-14-1997	
	AL	5,593,833		Morrison et al.	01-14-1997	
	AM	5,565,444		Mizushima et al.	10-15-1996	
	AN	5,532,391		DeLuca et al.	07-02-1996	
	AO	5,532,226		Demarest et al.	07-02-1996	
	AP	5,510,370		Hock	04-23-1996	
	AQ	5,414,098		DeLuca et al.	05-09-1995	
	AR	5,403,831		DeLuca et al.	04-04-1995	
	AS	5,354,773		Herslof et al.	10-11-1994	
	AT	5,300,687		Schwender et al.	04-05-1994	

FOREIGN PATENT DOCUMENTS							
Examiner Initials*	Cite No.	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Office	Number	Kind Code (if known)			
R	AU	PCT	WO 98/22113		Univ. of Florida Research Foundation	05-28-1998	
	AV	PCT	WO 98/31381		Univ. of Florida Research Foundation	07-23-1998	
	AW	PCT	WO 95/26719		Arcturus Pharmaceutical Corp.	10-12-1995	
Examiner		[Signature]				Date	10/20/02

[illegible]

Please type a plus sign (+) inside this box



PTO/SB/08A (10-96)

Approved for use through 10/31/99. OMB 0651-0031


Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

5, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>				Complete if Known	
				Application Number	09/414,091
				Filing Date	October 7, 1999
				First Named Inventor	Stavros C. Manolagas, et al.
				Group Art Unit	1614
				Examiner Name	
Sheet	1	of	1	Attorney Docket No.	06572.105002

U.S. PATENT DOCUMENTS						
Examiner Initials*	Cite No.	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code (if known)			
<i>me</i>	FA	5,362,720		Labrie	11-08-1994	
<i>st</i>	FB	5,189,212		Ruenitz	02-23-1993	

FOREIGN PATENT DOCUMENTS							
Examiner Initials*	Cite No.	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Office	Number	Kind Code (if known)			
Examiner		<i>[Signature]</i>				Date	10/20/03



Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Complete if Known			
		Application Number	09/414,091		
		Filing Date	October 7, 1999		
		First Named Inventor	Stavros C. Manolagas, et al.		
		Group Art Unit	1614		
Sheet	4	of	5	Examiner Name	
				Attorney Docket No.	06572.105002

OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS				
Examiner Initials*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.		
	DA	BELLIDO, T. et al. <u>Overexpression of Bcl-2 Renders Osteoblastic Cells Refractory to Glucocorticoid-Induced Apoptosis</u> , Bone, 23:S324, 1998		
	DB	BELLIDO, T. et al. <u>Regulation of Interleukin-6, Osteoclastogenesis, and Bone Mass by Androgens</u> , J. Clin. Invest. 95:2886-2895 (1995)		
	DC	BERGGREN, M. et al. <u>Glutathione Biosynthesis in the Isolated Perfused Rat Lung: Utilization of Extracellular Glutathione</u> , Federation European Biochemical Societies, 176: 189-192 (1984)		
	DD	DEMPSTER, D.W., <u>Exploiting and Bypassing the Bone Remodeling Cycle to Optimize the Treatment of Osteoporosis</u> , Journal of Bone and Mineral Research. 12:1152-1154 (1997)		
	DE	DEMPSTER, D.W. <u>New Concepts in Bone Remodeling</u> In: Dynamics of Bone and Cartilage Metabolism (1999) Academic Press 261-273.		
	DF	ELLIS, E. F. et al., <u>Restoration of cerebrovascular responsiveness to hyperventilation by the oxygen radical scavenger n-acetylcysteine following experimental traumatic brain injury</u> , Journal of Neurosurgery. 75:774-779 (1991)		
	DG	ETTINGER, B. et al., <u>Reduction of Vertebral Fracture Risk in Postmenopausal Women With Osteoporosis Treated with Raloxifene</u> , Journal of the American Medical Association. 282:637-645 (1999)		
	DH	FITZPATRICK, L.A. <u>Selective Estrogen Receptor Modulators and Phytoestrogens: New Therapies for the Postmenopausal Women</u> Mayo Clin. Proc. 74: 601-607 (1999)		
	DI	HUGHES, D.E. et al., <u>Estrogen promotes apoptosis of murine osteoclasts mediated by TGF-β</u> , Nature Medicine. 2:10:1132-1136 (1996)		
	DJ	JILKA, R.L. et al., <u>Osteoblast Programmed Cell Death (Apoptosis): Modulation by Growth Factors and Cytokines</u> , Journal of Bone and Mineral Research. 13:793-802 (1998)		
	DK	JILKA, R.L. et al., <u>Increased Osteoclast Development After Estrogen Loss: Mediation by Interleukin-6</u> , Science 257:88-91 (1992)		
	DL	JILKA, R.L. et al., <u>Linkage of Decreased Bone Mass with Impaired Osteoblastogenesis in a Murine Model of Accelerated Senescence</u> , The Journal of Clinical Investigation. 97:1732-1740 (1996)		
	DM	JILKA, R.L. et al., <u>Loss of Estrogen Upregulates Osteoblastogenesis in the Murine Bone Marrow. Evidence of Autonomy from Factors Released during Bone Resorption</u> , The American Society for Clinical Investigation, Inc. 101:1942-1950 (1998)		
	DN	JILKA, R.L. et al., <u>Increased bone formation by prevention of osteoblast apoptosis with parathyroid hormone</u> , The Journal of Clinical Investigation. 104:439-446 (1999)		
	DO	KAMEDA, T. et al., <u>Estrogen Inhibits Bone Resorption by Directly Inducing Apoptosis of the Bone-resorbing Osteoclasts</u> , The Journal of Experimental Medicine. 186:489-495 (1997)		
	DP	KNIGHT, K.R. et al., <u>Enhancement of ischaemic rabbit skin flap survival with the antioxidant and free-radical scavenger N-acetylcysteine</u> , Clinical Science. 81:31-36 (1991)		
Examiner's Signature			Date Considered	10/20/23



Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Complete if Known	
				Application Number	09/414,091
				Filing Date	October 7, 1999
				First Named Inventor	Stavros C. Manolagas, et al.
				Group Art Unit	1614
Examiner Name					
Sheet	5	of	5	Attorney Docket No.	06572.105002

OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS					
Examiner Initials*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.			
JL	EA	LALITHA, T. et al., <u>Effect of N-Acetyl-cysteine, D-Penicillamine and Buthionine Sulfoximine on Glutathione Levels and CNS Oxygen Toxicity in Rats</u> , Pharmacology & Toxicology. 66:56-61 (1990)			
	EB	MANOLAGAS, S.C. et al., <u>Bone Marrow, Cytokines, and Bone Remodeling; Emerging Insights into the Pathophysiology of Osteoporosis</u> , New England Journal of Medicine. 332:305-311 (1995)			
	EC	NORRIS et al. Science 285:744-746 (1999)			
	ED	PAIGE, L.A. et al., <u>Estrogen receptor (ER) modulators each induce distinct conformational changes in ER and ER</u> , Proc. Natl. Acad. Sci. USA. 96:3999-4004 (1999)			
	EE	PARFITT, A.M., <u>Bone-Forming Cells in Clinical Conditions</u> In: Bone Vol. 1 The osteoblast and osteocyte. 351-430 (1996) CRC Press, Boca Raton			
	EF	PLOTKIN, L.I. et al., <u>Bisphosphonates Prevent Glucocorticoid-Induced Apoptosis of Osteocytes In Vitro: a Putative Mechanism Influencing Mechanosensing</u> , Bone. 23:S157 (1998)			
	EG	RAISZ, L.G., <u>Estrogen and bone: New pieces to the puzzle</u> , Nature Medicine. 2:1077-1078 (1996)			
	EH	SMILKSTEIN, M.J. et al., <u>Efficacy of Oral N-Acetylcysteine in the Treatment of Acetaminophen Overdose</u> , The New England Journal of Medicine. 319:1557-1562 (1988)			
	EI	SNYDER, P.J. et al., <u>Effect of Testosterone Treatment on Bone Mineral Density in Men Over 65 Years of Age</u> J. Clin. Endocrin. Metab. 84: 1966-1972 (1999).			
	EJ	SUN, J. et al., <u>Novel Ligands that Function as Selective Estrogens or Antiestrogens for Estrogen Receptor- or Estrogen Receptor-</u> , Endocrinology. 140:800-804 (1999)			
	EK	WEINSTEIN, R.S. et al., <u>The Effects of Androgen Deficiency on Murine Bone Remodeling and Bone Mineral Density are Mediated via Cells of the Osteoblastic Lineage</u> , Endocrinology. 138:4013-4021 (1997)			
	EL	WEINSTEIN, R.S. et al., <u>Inhibition of Osteoblastogenesis and Promotion of Apoptosis of Osteoblasts and Osteocytes by Glucocorticoids</u> , The Journal of Clinical Investigation. 102:274-282 (1998)			
	EM	WEINSTEIN, S. et al., <u>Anatomic Juxtaposition of Apoptotic Osteocytes and Avascular Necrosis in Femurs from Patients with Glucocorticoid Excess</u> , Bone. 23:S461 (1998)			
	EN	Catalogue from Steroids, Inc. PO Box 310, Wilton, NH 03086 (undated)			
EO	SPARKS, A.B. et al. <u>Screening phage-displayed peptide libraries</u> . In: Phage Display of Peptides and Proteins, A Laboratory Manual. 227-253 (1996) Academic Press, San Diego.				
Examiner's Signature				Date Considered	10/20/03



Please type a plus sign (+) inside this box ☐

PTO/SB/08A (10-96)

Approved for use through 10/31/99. OMB 0651-0031

Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

5, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Complete if Known	
				Application Number	09/414,091
				Filing Date	October 7, 1999
				First Named Inventor	Stavros C. Manolagas, et al.
				Group Art Unit	1614
Sheet	2	of	5	Examiner Name	
				Attorney Docket No.	06572.105002

U.S. PATENT DOCUMENTS						
Examiner Initials*	Cite No.	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code (if known)			
11	BA	5,260,290		DeLuca et al.	11-09-1993	
	BB	5,208,219		Ogawa et al.	05-04-1993	
	BC	5,183,815		Saari et al.	02-02-1993	
	BD	5,164,368		Recker	11-17-1992	
	BE	5,140,864		DeLuca et al.	04-14-1992	
	BF	5,118,667		Adams et al.	06-02-1992	
	BG	5,071,655		Baylink	12-10-1991	
	BH	5,001,118		Maeda et al.	03-19-1991	
	BI	4,973,584		DeLuca et al.	11-27-1990	
	BJ	4,970,237		Jensen et al.	11-13-1990	
	BK	4,870,063		Binderup et al.	09-26-1989	
	BL	4,870,054		Recker	09-26-1989	
	BM	4,833,125		Neer et al.	05-23-1989	
	BN	4,710,382		Recker	12-01-1987	
	BO	4,619,920		DeLuca et al.	10-28-1986	

FOREIGN PATENT DOCUMENTS							
Examiner Initials*	Cite No.	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Office	Number	Kind Code (if known)			
Examiner						Date	10/20/03

Please type a plus sign (+) inside this box →

PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031



U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

RECEIVED

Substitute for form 1449A/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary) FEB 15 2002		Application Number	09/414,091
		Filing Date	October 7, 1999
		First Named Inventor	Manolagas et al.
		Group Art Unit	1617
		Examiner Name	Criares
		Attorney Docket Number	06572.105002
Sheet	of	2	

U.S. PATENT DOCUMENTS						
Examiner Initials *	Cite No. ¹	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pgs, Clms, Lns, Where Relevant Passages/Relevant Figs Appear
		Number	Kind Code (if known)			
JK	AA	5,071,773		Evans <i>et al.</i>	12/10/1991	
	AB	5,298,429		Evans <i>et al.</i>	03/29/1994	
	AC	5,545,634		Labrie <i>et al.</i>	08/13/1996	
	AD	5,506,102		McDonnell	04/09/1996	
	AE	5,554,601		Simpkins <i>et al.</i>	09/10/1996	
	AF	5,567,695		Labrie	10/22/1996	
	AG	5,846,960		Labrie	12/08/1998	
	AH	5,877,007		Housey	03/02/1999	
	AI	6,080,779		Gasper <i>et al.</i>	06/27/2000	


FOREIGN PATENT DOCUMENTS								
Examiner Initials *	Cite No. ¹	Foreign Patent Document			Date of Publication of Cited Document DD-MM-YYYY	Country	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Office ³	Number	Kind Code ² (if known)				
	AJ	EP	0 753 523	A1	15/01/1997	EPO		
	AK	WO	00/19823	A1	13/04/2000	PCT		
	AL	WO	00/20007	A1	13/04/2000	PCT		
	AM	WO	00/20625	A1	13/04/2000	PCT		
	AN	WO	00/37681	A1	29/06/2000	PCT		
	AO	WO	99/54728	A3	28/10/1999	PCT		

Examiner Signature		Date Considered	10/20/03
--------------------	--	-----------------	----------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box → 

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Submitted for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT				Complete if Known	
				Application Number	09/414,091
				Filing Date	October 7, 1999
				First Named Inventor	Manolagas et al.
				Group Art Unit	1617
Sheet	2	of	2	Attorney Docket Number	06572. 105002

RECEIVED
 FEB 22 2002
 PCH CENTER 1600/2900



OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS			
Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ⁶
PK ↓	BA	ALESSI, D.R., et al. "PD 098059 Is a Specific Inhibitor of the Activation of Mitogen-activated Protein Kinase in Vitro and In Vivo," J. Biol. Chem. 270: 27489-27494 (1995).	
	BB	BELLIDO, T. et al. "Activation of the Janus Kinase/STAT (Signal Transducer and Activator of Transcription) Signal Transduction Pathway by Interleukin-6-Tye Cytokines Promotes Osteoblast Differentiation," Endocrinology 138:3666-3676 (1997).	
	BC	FALKENSTEIN et al. "Nongenomically initiated steroid actions." Eur J Clin Invest. Dec 30 Suppl 3:51-4 (2000).	
	BD	FINKEL. "Phyto-oestrogens: the way to postmenopausal health." The Lancet. Nov 28;352(9142):1762.(1998).	
	BE	HILL et al. "Multiple extracellular signals promote osteoblast survival and apoptosis." Endocrinology 138(9): 3849-3858(1997).	
	BF	KATO, Y. et al., "Establishment of an Osteocyte-like Cell Line, MLO-Y4," Journal of Bone and Mineral Research," 12:2014-2023 (1997).	
	BH	PARFITT. "Calcitriol for postmenopausal osteoporosis," Ann Intern Med. 1990 Jan 15;112(2):147	
		XIA, Z. et al., "Opposing Effects of ERK and JNK-p38 MAP Kinases on Apoptosis," Science. 270:1326-1331 (1995).	

Examiner Signature		Date Considered	2/20/03
--------------------	---	-----------------	---------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.